Welcome to our dedicated page for Co-Diagnostics news (Ticker: CODX), a resource for investors and traders seeking the latest updates and insights on Co-Diagnostics stock.
Co-Diagnostics, Inc. (NASDAQ: CODX) is a pioneering molecular diagnostics company based in Sandy, Utah. The company is renowned for its unique, patented technology that significantly enhances the speed, performance, and cost-efficiency of DNA testing for a variety of diseases compared to traditional methods. Co-Diagnostics focuses on the development, manufacturing, and commercialization of its proprietary technologies through sales, development, and licensing agreements.
Co-Diagnostics’ core technology is protected by multiple patents and trade secrets, enabling revolutionary approaches in molecular diagnostics. These innovations have been utilized to develop a range of assays in the infectious disease sector, demonstrating the technology's exceptional capabilities. The company's patented inventions stem from advanced mathematical models designed by Dr. Brent C. Satterfield.
The firm’s product portfolio includes diagnostic tests for diseases such as tuberculosis, Zika, hepatitis B and C, malaria, dengue, and HIV. These tests utilize the detection and analysis of nucleic acid molecules (DNA or RNA) to provide accurate and efficient diagnostics. Co-Diagnostics also leverages its proprietary technology to create tests for its Co-Dx PCR platform, which includes at-home and point-of-care solutions.
One of the notable collaborations of Co-Diagnostics is its joint venture with CoSara Diagnostics Pvt Ltd in India. This partnership has led to regulatory clearance from India’s Central Drugs Standard Control Organization (CDSCO) for multiple diagnostic tests, including the SARAPLEX™ Influenza Multiplex (IFM) Test Kit, which differentiates between Influenza A and B strains.
Recently, Co-Diagnostics announced significant milestones, such as the opening of new manufacturing facilities in Salt Lake City, Utah, and Ranoli, India. These facilities will enhance the production of the company’s novel Co-Dx PCR Pro™ instrument and test cups, as well as the Co-Primers™ chemistry that is vital for its PCR diagnostic tests. The Salt Lake City facility, inaugurated with support from local dignitaries and business leaders, marks a critical step in expanding the company's production capabilities.
The company’s forward-looking strategies include submitting an Emergency Use Authorization (EUA) to the FDA for the Co-Dx PCR Pro™ instrument, mobile app, and COVID-19 test. This submission is part of Co-Diagnostics’ effort to decentralize PCR diagnostics and extend its reach to at-home and point-of-care settings. The company is also developing tests for tuberculosis, multiplex respiratory infections, and HPV, among others.
Co-Diagnostics’ financial performance and strategic initiatives are regularly discussed through conference calls and webcasts, involving key executives such as CEO Dwight Egan and CFO Brian Brown. The company remains committed to innovation and growth, aiming to provide accessible and high-quality diagnostic solutions worldwide.
Co-Diagnostics, Inc. (CODX) announced that its Logix Smart™ SARS-CoV-2 DS test has received regulatory authorization as an in vitro diagnostic (IVD) for COVID-19 detection in markets accepting CE markings. This test allows for direct saliva sampling, eliminating the need for RNA extraction, which can reduce costs and increase testing throughput. CEO Dwight Egan emphasized that this innovation could significantly aid in ongoing testing efforts, especially in areas lagging in vaccination rates. The CE marking facilitates immediate sales in the European Community and other global markets.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) will present virtually at the 28th International Biodetection Technologies Conference on June 18. The focus will be on point-of-care diagnostics to enhance global health and biodefense. The company's presentation at 12:30 pm ET will detail their rapid PCR testing platform aimed at normalizing daily activities during the COVID-19 pandemic. Additionally, Co-Diagnostics will showcase its products at the CARPHA Health Research Conference from June 16-19, focusing on health issues in the Caribbean region.
Co-Diagnostics, Inc. (Nasdaq: CODX) will release its first-quarter 2021 results on May 13, 2021, after the market close. A conference call and webcast will follow at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan and CFO Brian Brown. Investors can access the event on the company's website. Co-Diagnostics specializes in developing and marketing advanced molecular diagnostic tests using unique technology for detecting nucleic acid molecules, and provides licensing for specific tests across various industries.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced its participation in a webinar on April 29, 2021, featuring Dr. Heather Fehling from Clinical Reference Lab. The event will discuss PCR testing for COVID-19, highlighting non-invasive saliva tests and new applications in response to emerging strains. Co-Diagnostics’ technology is used in CRL's saliva PCR test, which boasts high sensitivity and specificity, with results typically available in 24 hours. This initiative aims to enhance testing accessibility and application in various settings.
Co-Diagnostics, Inc. (Nasdaq: CODX) announced the successful use of its Logix Smart™ COVID-19 Test Kit by Australian researchers, with results published in the Journal of Medical Microbiology. The study showed analytical sensitivity of 1010 viral copies per ml, comparable to other tests used in Western Australia. The test performed well on clinical samples, demonstrating complete concordance with the comparison assay. CEO Dwight Egan emphasized the test's robustness and the company’s commitment to affordable molecular diagnostics in remote locations.
On March 31, 2021, Co-Diagnostics, Inc. CEO Dwight Egan discussed the company's FY2020 earnings on Yahoo! Finance, emphasizing the importance of at-home and point-of-care testing in achieving normalization post-COVID-19. He highlighted the development of a new platform aimed at quick and accurate COVID-19 testing, while emphasizing that continued testing will complement vaccine distribution. The company has established a global distributor network and is expanding its diagnostic product offerings, including liquid biopsy technology, to meet future demands.
Co-Diagnostics, Inc. (NASDAQ: CODX) reported strong financial results for Q4 and full year 2020, driven largely by its Logix Smart™ COVID-19 Test. Fourth-quarter revenue reached $27.1 million with a gross profit margin of 84.1%, leading to a net income of $12.8 million, compared to a loss of $1.7 million in Q4 2019. For the full year, revenue soared to $74.6 million, a significant increase from the previous year, with net income of $42.5 million. The company anticipates ongoing demand for COVID-19 testing in 2021 and has initiated development of new testing platforms.
Co-Diagnostics, Inc. (Nasdaq: CODX) will announce its fourth-quarter and full-year 2020 financial results on March 25, 2021, after market close. The company will host a conference call and webcast at 4:30 p.m. EDT on the same day, featuring CEO Dwight Egan, CFO Brian Brown, and General Counsel Reed Benson. Investors can access the live event via the company's website. For those unable to attend live, a recording will be made available later.
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) announced its participation in the Maxim Group LLC and M Vest LLC Inaugural Emerging Growth Virtual Conference on March 17-18, 2021. The presentation will cover the company's rapid PCR diagnostics platform supporting COVID-19 testing to help normalize daily routines. For registration details, visit the conference link. An archived version of the presentation will be available on the Co-Diagnostics website post-event. The company focuses on developing advanced molecular diagnostic tests using its proprietary technology.
FAQ
What is the current stock price of Co-Diagnostics (CODX)?
What is the market cap of Co-Diagnostics (CODX)?
What does Co-Diagnostics, Inc. specialize in?
Where is Co-Diagnostics headquartered?
What diseases can Co-Diagnostics' tests diagnose?
What is the Co-Dx PCR platform?
What recent achievements has Co-Diagnostics made?
What is the CoSara Diagnostics joint venture?
What are Co-Primers?
What regulatory clearances has Co-Diagnostics received in India?
What is the FDA status of Co-Diagnostics' products?
Who are the key executives at Co-Diagnostics?
